全文获取类型
收费全文 | 17770篇 |
免费 | 1285篇 |
国内免费 | 60篇 |
专业分类
耳鼻咽喉 | 48篇 |
儿科学 | 990篇 |
妇产科学 | 338篇 |
基础医学 | 1770篇 |
口腔科学 | 21篇 |
临床医学 | 1874篇 |
内科学 | 6153篇 |
皮肤病学 | 257篇 |
神经病学 | 1605篇 |
特种医学 | 90篇 |
外科学 | 1862篇 |
综合类 | 309篇 |
一般理论 | 1篇 |
预防医学 | 1342篇 |
眼科学 | 732篇 |
药学 | 681篇 |
中国医学 | 26篇 |
肿瘤学 | 1016篇 |
出版年
2024年 | 25篇 |
2023年 | 158篇 |
2022年 | 105篇 |
2021年 | 184篇 |
2020年 | 156篇 |
2019年 | 81篇 |
2018年 | 324篇 |
2017年 | 327篇 |
2016年 | 372篇 |
2015年 | 400篇 |
2014年 | 313篇 |
2013年 | 555篇 |
2012年 | 1446篇 |
2011年 | 1581篇 |
2010年 | 533篇 |
2009年 | 542篇 |
2008年 | 1616篇 |
2007年 | 1581篇 |
2006年 | 1358篇 |
2005年 | 1460篇 |
2004年 | 1509篇 |
2003年 | 1607篇 |
2002年 | 1178篇 |
2001年 | 897篇 |
2000年 | 184篇 |
1999年 | 100篇 |
1998年 | 119篇 |
1997年 | 90篇 |
1996年 | 51篇 |
1995年 | 34篇 |
1994年 | 38篇 |
1993年 | 24篇 |
1992年 | 16篇 |
1991年 | 14篇 |
1990年 | 24篇 |
1989年 | 14篇 |
1988年 | 19篇 |
1987年 | 13篇 |
1986年 | 9篇 |
1985年 | 4篇 |
1984年 | 12篇 |
1983年 | 5篇 |
1982年 | 5篇 |
1981年 | 11篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1978年 | 4篇 |
1975年 | 2篇 |
1974年 | 2篇 |
1970年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
81.
Bozzette SA Joyce G McCaffrey DF Leibowitz AA Morton SC Berry SH Rastegar A Timberlake D Shapiro MF Goldman DP;HIV Cost Services Utilization Study Consortium 《The New England journal of medicine》2001,344(11):817-823
BACKGROUND: The introduction of expensive but very effective antiviral medications has led to questions about the effects on the total use of resources for the care of patients with human immunodeficiency virus (HIV) infection. We examined expenditures for the care of HIV-infected patients since the introduction of highly active antiretroviral therapy. METHODS: We interviewed a random sample of 2864 patients who were representative of all American adults receiving care for HIV infection in early 1996, and followed them for up to 36 months. We estimated the average expenditure per patient per month on the basis of self-reported information about care received. RESULTS: The mean expenditure was $1,792 per patient per month at base line, but it declined to $1,359 for survivors in 1997, since the increases in pharmaceutical expenditures were smaller than the reductions in hospital costs. Use of highly active antiretroviral therapy was independently associated with a reduction in expenditures. After adjustments for the interview date, clinical status, and deaths, the estimated annual expenditure declined from $20,300 per patient in 1996 to $18,300 in 1998. Expenditures among subgroups of patients varied by a factor of as much as three. Pharmaceutical costs were lowest and hospital costs highest among underserved groups, including blacks, women, and patients without private insurance. CONCLUSIONS: The total cost of care for adults with HIV infection has declined since the introduction of highly active antiretroviral therapy. Expenditures have increased for medications but have declined for other services. However, there are large variations in expenditures across subgroups of patients. 相似文献
82.
83.
84.
A reevaluation of the duration of survival after the onset of dementia 总被引:15,自引:0,他引:15
Wolfson C Wolfson DB Asgharian M M'Lan CE Ostbye T Rockwood K Hogan DB;Clinical Progression of Dementia Study Group 《The New England journal of medicine》2001,344(15):1111-1116
BACKGROUND: Dementia shortens life expectancy; estimates of median survival after the onset of dementia have ranged from 5 to 9.3 years. Previous studies of people with existing dementia, however, may have underestimated the deleterious effects of dementia on survival by failing to consider persons with rapidly progressive illness who died before they could be included in a study (referred to as length bias). METHODS: We used data from the Canadian Study of Health and Aging to estimate survival from the onset of symptoms of dementia; the estimate was adjusted for length bias. A random sample of 10,263 subjects 65 years old or older from throughout Canada was screened for cognitive impairment. For those with dementia, we ascertained the date of onset and conducted follow-up for five years. RESULTS: We analyzed data on 821 subjects, of whom 396 had probable Alzheimer's disease, 252 had possible Alzheimer's disease, and 173 had vascular dementia. For the group as a whole, the unadjusted median survival was 6.6 years (95 percent confidence interval, 6.2 to 7.1). After adjustment for length bias, the estimated median survival was 3.3 years (95 percent confidence interval, 2.7 to 4.0). The median survival was 3.1 years for subjects with probable Alzheimer's disease, 3.5 years for subjects with possible Alzheimer's disease, and 3.3 years for subjects with vascular dementia. CONCLUSIONS: Median survival after the onset of dementia is much shorter than has previously been estimated. 相似文献
85.
Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients 总被引:4,自引:0,他引:4
Lichtenstein KA Delaney KM Armon C Ward DJ Moorman AC Wood KC Holmberg SD;HIV Outpatient Study Investigators 《Journal of acquired immune deficiency syndromes (1999)》2003,32(1):48-56
To identify clinical factors associated with the incidence of HIV-1-associated lipoatrophy, HIV-1-infected patients in the HIV Outpatient Study (HOPS) were prospectively evaluated for clinical signs of lipoatrophy at two visits about 21 months apart. Development of lipoatrophy was analyzed in stratified and multivariate analyses for its relationship to immunologic, virologic, clinical, and drug treatment information for each patient. Of 337 patients with no lipoatrophy at Survey 1, 44 (13.1%) developed moderate or severe lipoatrophy between the two surveys. In multivariate analyses, significant risk factors for incident lipoatrophy were white race (OR = 5.2; 95% CI: 1.9-17.1; =.003), CD4 T-lymphocyte count at Survey 2 less than 100 cells/mm3 (OR = 4.2; 95% CI: 1.3-13.1; =.013), and body mass index (BMI) less than 24 kg/m2 (OR = 2.4; 95% CI: 1.1-5.4; =.024). Analyses that controlled for the severity of HIV illness demonstrated no significant association with use of or time on any antiretroviral agent or class of agents and the development of lipoatrophy. Some host factors and factors associated with previous or current severity of HIV infection, especially CD4 T-lymphocyte cell count, appeared to have the strongest association with incidence of lipoatrophy. 相似文献
86.
87.
88.
89.
Intranasal and inhaled fluticasone propionate for pollen-induced rhinitis and asthma 总被引:3,自引:0,他引:3
Dahl R Nielsen LP Kips J Foresi A Cauwenberge P Tudoric N Howarth P Richards DH Williams M Pauwels R;SPIRA Study Group 《Allergy》2005,60(7):875-881
BACKGROUND: Studies suggest that nasal treatment might influence lower airway symptoms and function in patients with comorbid rhinitis and asthma. We investigated the effect of intranasal, inhaled corticosteroid or the combination of both in patients with both pollen-induced rhinitis and asthma. METHODS: A total of 262 patients were randomized to 6 weeks' treatment with intranasal fluticasone propionate (INFP) 200 microg o.d., inhaled fluticasone propionate (IHFP) 250 microg b.i.d., their combination, or intranasal or inhaled placebo, in a multicentre, double-blind, parallel-group study. Treatment was started 2 weeks prior to the pollen season and patients recorded their nasal and bronchial symptoms twice daily. Before and after 4 and 6 weeks' treatment, the patients were assessed for lung function, methacholine responsiveness, and induced sputum cell counts. RESULTS: Intranasal fluticasone propionate significantly increased the percentages of patients reporting no nasal blockage, sneezing, or rhinorrhoea during the pollen season, compared with IHFP or intranasal or inhaled placebo. In contrast, only IHFP significantly improved morning peak-flow, forced expiratory volume in 1 second (FEV1) and methacholine PD20, and the seasonal increase in the sputum eosinophils and methacholine responsiveness. CONCLUSIONS: In patients with pollen-induced rhinitis and asthma, the combination of intranasal and IHFP is needed to control the seasonal increase in nasal and asthmatic symptoms. 相似文献
90.
Morand-Joubert L Marcellin F Launay O Guiramand-Hugon S Gérard L Yeni P Aboulker JP;Agence Nationale de Recherches sur le SIDA Study Group 《Journal of acquired immune deficiency syndromes (1999)》2005,38(3):268-276
Cellular HIV-1 DNA level was sequentially measured by quantitative polymerase chain reaction in 141 patients not previously treated with highly active antiretroviral therapy (HAART), who were enrolled in a 72-week randomized trial (ANRS 081 "Trianon") comparing 2 regimens, including 3 drugs from 2 classes (indinavir + stavudine + lamivudine, group 1) or 3 classes (indinavir + stavudine + nevirapine, group 2). The median decrease from baseline to week 72 in cellular HIV-1 DNA level was not significantly different between the 2 groups (0.54 and 0.45 log10 copies/10 peripheral blood mononuclear cells [PBMCs] in groups 1 and 2, respectively), whereas a higher proportion of patients maintained a plasma HIV-1 RNA level less than 20 copies/mL at week 72 in group 1 than in group 2 (79% and 52%; P = 0.0009). Furthermore, the difference in cellular HIV-1 DNA decrease from baseline to week 72 between patients who achieved a plasma HIV-1 RNA level less than 20 copies/mL at week 72 and those who did not was not statistically significant (0.54 and 0.45 log10 copies/10 PBMCs, respectively; P = 0.14). The decay in cellular HIV-1 DNA from baseline to week 72 was higher in antiretroviral-naive patients than in pretreated patients (0.55 and 0.23 log10 copies/10 PBMCs, respectively; P = 0.0008). The cellular HIV-1 DNA level change under therapy was best fitted to a 2-phase decay model with a junction point at week 16, from which its half-life was estimated at 18 weeks during the initial phase and at 104 weeks thereafter. In conclusion, the changes under therapy in cellular HIV-1 DNA level, which were mostly coincident to those of plasma HIV-1 RNA, did not add significant information to the comparison of the viral efficacy of the 2 studied regimens. 相似文献